Chronic disease management practices and factors associated with health‐related quality‐of‐life for persons with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

医学 髓系白血病 内科学 生活质量(医疗保健) 疾病 多元分析 酪氨酸激酶抑制剂 疾病管理 不利影响 癌症 护理部 帕金森病
作者
Qing Zhang,Zhen Li,Yujie Hou,Hui-Bing Dang,Jianling Chen,Lixin Liang,Qian Wang,Changsong Cao,Hong Zhao,Ruirui Gui,Yingling Zu,Jingming Zhou,Fengkuan Yu,Juan Wang,Yongping Song,Yanli Zhang
标识
DOI:10.21037/apm-22-158
摘要

The main objective of this study was to explore health-related quality of life (HRQoL) profiles, chronic disease management practices and key factors associated with HRQoL in 540 patients with chronic myeloid leukemia in chronic phase (CML-CP) administered tyrosine kinase inhibitors (TKIs).Adult CML-CP patients treated with TKIs in Henan Cancer Hospital from March 2015 to October 2019 were assessed via questionnaires, including demographic characteristics, TKI medications, participation in CML disease management, and HRQoL, in a cross-sectional investigation. Respondents were anonymous. Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu) was used to measure HRQoL. A multivariate linear regression model with stepwise entry was used to investigate variables independently associated with HRQoL domain and total scores.Totally, 540 respondents were included; 302 (55.93%) were male. Mean participant age was 42.90±13.00 years; 169 (31.3%), 178 (32.9%) and 193 (35.7%) individuals had a low, moderate or high disease management level, respectively. Except for insignificant event-free survival information, participants with higher disease management levels also had significantly higher rates of completing re-examination, drug withdrawal, cytogenetic response (CcyR) and/or major molecular response (MMR) (all P<0.01). Moreover, higher disease management level was accompanied by eight significantly higher HRQoL domains (all P<0.01). In multivariate linear regression analysis, variables significantly associated with a higher HRQoL included: (I) high disease management level (B=3.68, P=0.046); (II) transportation convenience (B=6.67, P<0.001); (III) family annual income >10,000 CNY (B=5.97, P<0.001); (IV) completed re-examination (B=4.58, P=0.036); (V) MMR (B=3.75, P=0.021) and CcyR (B=5.15, P=0.035). Female sex (B=-3.53, P=0.010), single status or divorce (B=-1.89 and -2.94, P=0.005 and 0.011), and low education level (B=-1.44, P=0.019) were significantly associated with lower HRQoL.Higher disease management level was significantly associated with higher elevated treatment efficacy and HRQoL in Chinese individuals with CML-CP administered TKIs. These data indicate the importance of chronic disease management on people's HRQoL and clinical outcome.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
烟花应助123号采纳,获得10
刚刚
超帅的遥完成签到,获得积分10
刚刚
Zxc完成签到,获得积分10
1秒前
lbt完成签到 ,获得积分10
2秒前
yao完成签到 ,获得积分10
3秒前
3秒前
5秒前
6秒前
6秒前
doudou完成签到 ,获得积分10
6秒前
BCS完成签到,获得积分10
6秒前
领导范儿应助KYN采纳,获得10
6秒前
7秒前
独特的莫言完成签到,获得积分10
9秒前
lin发布了新的文献求助10
10秒前
aero完成签到 ,获得积分10
12秒前
123号完成签到,获得积分10
14秒前
充电宝应助TT采纳,获得10
16秒前
17秒前
17秒前
英姑应助荒野星辰采纳,获得10
19秒前
19秒前
YHY完成签到,获得积分10
21秒前
科研通AI5应助魏伯安采纳,获得10
21秒前
caoyy发布了新的文献求助10
21秒前
22秒前
23秒前
张喻235532完成签到,获得积分10
24秒前
失眠虔纹发布了新的文献求助10
25秒前
香蕉觅云应助糊涂的小伙采纳,获得10
25秒前
25秒前
sutharsons应助科研通管家采纳,获得200
27秒前
打打应助科研通管家采纳,获得10
27秒前
axin应助科研通管家采纳,获得10
27秒前
丘比特应助科研通管家采纳,获得10
27秒前
小蘑菇应助科研通管家采纳,获得10
27秒前
上官若男应助科研通管家采纳,获得10
27秒前
无花果应助科研通管家采纳,获得10
27秒前
27秒前
李健应助科研通管家采纳,获得10
27秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Ensartinib (Ensacove) for Non-Small Cell Lung Cancer 1000
Unseen Mendieta: The Unpublished Works of Ana Mendieta 1000
Bacterial collagenases and their clinical applications 800
El viaje de una vida: Memorias de María Lecea 800
Luis Lacasa - Sobre esto y aquello 700
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3527998
求助须知:如何正确求助?哪些是违规求助? 3108225
关于积分的说明 9288086
捐赠科研通 2805889
什么是DOI,文献DOI怎么找? 1540195
邀请新用户注册赠送积分活动 716950
科研通“疑难数据库(出版商)”最低求助积分说明 709849